尿液外泌体mRNA特征诊断肾移植排斥反应的发现与验证
该研究基于175例患者匹配活检的192份尿液样本,分离尿液外泌体mRNA并开发排斥反应特征。外泌体mRNA特征区分全部原因排斥与无排斥的AUC为0.93,优于eGFR变化(AUC 0.57);另可区分T细胞介导与抗体介导排斥(AUC 0.87)。
要点
- 尿液外泌体mRNA特征诊断肾移植排斥AUC达0.93,阴性预测值93.3%。
- 该特征显著优于现行eGFR变化标准(AUC 0.57)。
- 另可区分T细胞介导与抗体介导排斥,AUC 0.87。
核心结论
- 尿液外泌体来源的mRNA特征可作为无创筛查肾移植排斥反应的有力工具。
研究设计与样本
- 使用175例临床指征肾移植活检患者的192份匹配尿液样本(共220份中选取),分离尿液外泌体mRNA并基于差异基因表达开发排斥特征,采用交叉验证评估性能。
主要发现
- 外泌体mRNA特征区分全部原因排斥与无排斥的AUC为0.93(95%CI 0.87-0.98),阴性预测值93.3%,阳性预测值86.2%。
- 现行eGFR变化标准诊断排斥的AUC为0.57(95%CI 0.49-0.65)。
- 另一基因特征区分T细胞介导排斥与抗体介导排斥的AUC为0.87(95%CI 0.76-0.97),阴性预测值90.6%,阳性预测值77.8%。
临床怎么用
- 该外泌体mRNA特征有潜力辅助临床医生进行肾移植排斥反应的无创筛查与治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Developing a noninvasive clinical test to accurately diagnose kidney allograft rejection is critical to improve allograft outcomes. Urinary exosomes, tiny vesicles released into the urine that carry parent cells' proteins and nucleic acids, reflect the biologic function of the parent cells within the kidney, including immune cells. Their stability in urine makes them a potentially powerful tool for liquid biopsy and a noninvasive diagnostic biomarker for kidney-transplant rejection. METHODS: Using 192 of 220 urine samples with matched biopsy samples from 175 patients who underwent a clinically indicated kidney-transplant biopsy, we isolated urinary exosomal mRNAs and developed rejection signatures on the basis of differential gene expression. We used crossvalidation to assess the performance of the signatures on multiple data subsets. RESULTS: An exosomal mRNA signature discriminated between biopsy samples from patients with all-cause rejection and those with no rejection, yielding an area under the curve (AUC) of 0.93 (95% CI, 0.87 to 0.98), which is significantly better than the current standard of care (increase in eGFR AUC of 0.57; 95% CI, 0.49 to 0.65). The exosome-based signature's negative predictive value was 93.3% and its positive predictive value was 86.2%. Using the same approach, we identified an additional gene signature that discriminated patients with T cell-mediated rejection from those with antibody-mediated rejection (with an AUC of 0.87; 95% CI, 0.76 to 0.97). This signature's negative predictive value was 90.6% and its positive predictive value was 77.8%. CONCLUSIONS: Our findings show that mRNA signatures derived from urinary exosomes represent a powerful and noninvasive tool to screen for kidney allograft rejection. This finding has the potential to assist clinicians in therapeutic decision making.
引用
- El Fekih R, Hurley J, Tadigotla V, et al. Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection. J Am Soc Nephrol. 2021. PMID: 33658284. doi:10.1681/ASN.2020060850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。